We were grateful for the opportunity to attend and present at the AACR Annual Meeting last week, where three of our scientists highlighted some of the exciting work happening in our Vancouver lab.
June 5, 2023
To discuss the development of the Endometrial ProMisE Molecular Classifier, and the new NSMP study further, we are delighted to have Dr. Jessica McAlpine and Dr. Amy Jamieson, esteemed gynecological cancer surgeons at Vancouver General Hospital, who have been instrumental in the development and implementation of this innovative tool.
March 28, 2023
Imagia Canexia Health announced that three abstracts highlighting the company’s new learnings and tools will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19, 2023, at the Orange County Convention Center in Orlando, Florida.
March 27, 2023
Project ACTT (Access to Cancer Testing and Treatment) in Response to COVID-19 was a joint effort led by Imagia Canexia Health and supported by Digital Supercluster and partner institutions.
February 3, 2023
The theme for this year’s World Cancer Day is Close the Care Gap. Health equity is a pillar of our work at Imagia Canexia Health. So today our Chief Medical Officer, Dr. David Huntsman, is opening the conversation to showcase how our community-centered approach to cancer care is improving access to genomic-driven cancer care for all.
December 7, 2022
Read about the history of the Human Genome Project.
December 1, 2022
The holiday season is around the corner and we would like to inform everyone of our operation schedule over Christmas and New Year.
November 15, 2022
The entire month of November is Lung Cancer Awareness Month. ICH is opening up the conversation to showcase how our distributed data-driven approach is improving health equity in lung cancer cures.
October 24, 2022
We’re thrilled to announce that Imagia Canexia Health is a finalist for the Reuters Events Pharma Awards, in the Driving Health Equity category.
September 22, 2022
Appointment fortifies Imagia Canexia Health’s board with leading expertise in successfully scaling biopharma and diagnostics enterprises
Every Imagia Canexia Health report comes with therapeutic recommendations based on specific gene mutations and patient profiles, with clinical trials reviewed and selected by certified clinical molecular geneticists.